The article highlights Oracle and Tesla as two AI stocks with significant growth potential. Oracle's cloud computing segment is growing rapidly at 34% year-over-year, driven by major deals like its $300 billion agreement with OpenAI, though the company has taken on substantial debt to fund data center expansion. Tesla is pivoting toward mass production of its Optimus humanoid robot, with plans to launch at $20,000-$30,000 by end of next year, potentially transforming the company beyond electric vehicles.

The article recommends three discounted growth stocks with potential to double: Oracle, trading at a 60% discount from its 52-week high with a strong $523 billion backlog despite debt concerns; Figma, down 80% from its post-IPO high but showing strong product adoption with 136% net dollar retention; and Zscaler, down 55% since November but maintaining robust 26% revenue growth and approaching profitability.

The article identifies two major risks to stock market performance in 2026: Trump's tariff policies creating economic uncertainty and potential interest rate increases from a ballooning deficit, which could reduce stock attractiveness relative to bonds. While massive AI spending has boosted valuations, the article warns that depreciation expenses and potential failures of unprofitable AI companies could trigger significant market corrections.

Rosen Law Firm has filed class action lawsuits against Oracle Corporation, Corcept Therapeutics, and Endeavor Group Holdings on behalf of investors who purchased common stock during specified periods. The Oracle lawsuit alleges the company made false statements regarding its AI infrastructure strategy, resulting in massive CapEx increases without equivalent revenue growth and creating risks to debt, credit rating, and cash flow. Lead plaintiff deadlines vary by case, with investors encouraged to secure counsel.

While investor attention remains focused on AI mega-caps and high-growth tech stocks, several large-cap companies are quietly delivering strong performance in 2026. Caterpillar, Oracle, AbbVie, and Progressive are highlighted as steady, profitable performers with consistent earnings and strong balance sheets that offer superior risk-adjusted returns without the hype.

The global EMR systems market is valued at USD 31.51 billion in 2025 and is expected to reach USD 47.68 billion by 2035, growing at a CAGR of 4.23%. Growth is driven by government mandates, value-based care models, and AI-powered documentation. However, high implementation costs and physician adoption challenges pose constraints. The U.S. leads the market at USD 13.27 billion in 2025, while Asia Pacific shows the fastest growth at 5.42% CAGR.

Oracle stock has declined 37% in six months amid AI spending concerns. The article identifies three major red flags: (1) Oracle's $100 billion debt load to fund cloud infrastructure buildout while competitors AWS and Azure leverage existing profitability, (2) uncertainty around OCI's margins and revenue realization from deals potentially won through generous terms rather than superior technology, and (3) heavy dependence on OpenAI's continued capital commitments. The stock is characterized as high-risk, high-reward, suitable only for investors with very high risk tolerance.

The Portnoy Law Firm has announced a class action lawsuit on behalf of Oracle Corporation investors who purchased securities between June 12, 2025 and December 16, 2025. The lawsuit follows significant stock price declines triggered by Oracle's announcement of a $300 billion OpenAI contract, a subsequent $38 billion debt raise for AI infrastructure, and a December earnings call disclosure of an additional $15 billion in capital expenditure forecasts for fiscal 2026.

HSBC has downplayed concerns about AI replacing the SaaS sector, arguing that software will benefit from AI's development rather than be disrupted by it. The bank maintains that companies won't abandon established software vendors due to high switching costs and long-term contracts. Analysts including Wedbush's Dan Ives and Nvidia CEO Jensen Huang agree that AI will enhance rather than replace enterprise software, contradicting the recent $1 trillion market sell-off in software stocks.

Economist Mohamed El-Erian warns of a 'rational bubble' in AI where overinvestment is rampant, with many companies merely attaching 'AI labels' to attract capital. While the potential payoff justifies some overinvestment, the market is dangerously concentrated in a few hyperscalers like Nvidia. Combined with surging corporate debt and 'circular financing' among tech giants, a slowdown in AI adoption could trigger a significant sell-off and contaminate the broader economy, particularly impacting lower-income households already burdened by high debt.

Major tech hyperscalers have accumulated $662 billion in off-balance-sheet data center lease obligations that don't appear on their balance sheets under GAAP accounting. As AI infrastructure leases commence in coming years, over half a trillion dollars in assets will appear on corporate balance sheets, pressuring accounting metrics. Critics including Michael Burry allege companies are using aggressive accounting to mask true AI infrastructure costs and overstate hardware useful life.

The global healthcare predictive analytics market is projected to grow from USD 20.57 billion in 2025 to USD 140.02 billion by 2035, with a CAGR of 21.14%. Growth is driven by increasing EHR adoption, government mandates for healthcare digitalization, value-based care adoption, and emphasis on reducing hospital readmissions. The U.S. market alone is expected to reach USD 57.64 billion by 2035. Asia Pacific is experiencing the fastest growth at 23.15% CAGR, while North America maintains the largest market share at 44.72%.